American College of Cardiology

MARCH 12, 2025

According to a new study published in JACC, there is a strong dose-response relationship between cigarette smoking and three different domains of subclinical cardiovascular markers: inflammation, thrombosis and subclinical atherosclerosis.

Thrombosis 75

Thrombosis Atherosclerosis Article 75

American College of Cardiology

MARCH 29, 2025

Extended anticoagulant therapy with a reduced-dose of apixaban was noninferior to extended therapy with a full-dose of apixaban in preventing recurrent venous thromboembolism (VTE) in patients with active cancer and proximal deep-vein thrombosis or pulmonary embolism, based on findings from the API-CAT trial presented at ACC.25

Cancer 71

Cancer Thrombosis Embolism Pulmonary 71

American College of Cardiology

NOVEMBER 5, 2024

The following are key points to remember from a state-of-the art review on antithrombotic therapy in patients with high bleeding risk (HBR) noncardiac percutaneous interventions from the Working Group of Thrombosis of the Italian Society of Cardiology.

Thrombosis 74

Thrombosis Article 74

American College of Cardiology

OCTOBER 15, 2024

The following are key points to remember from a state-of-the-art review on antithrombotic therapy in patients at high bleeding risk (HBR) from the Working Group of Thrombosis of the Italian Society of Cardiology.

Thrombosis 73

Thrombosis Article 73

American College of Cardiology

FEBRUARY 4, 2025

The use of noncigarette tobacco products is associated with considerable cardiovascular risk, as demonstrated by relevant inflammation, thrombosis and atherosclerosis markers, according to a cross-sectional study published Jan.

Thrombosis 63

Thrombosis Atherosclerosis Article 63

American College of Cardiology

FEBRUARY 26, 2025

26 in JACC: Basic to Translational Science highlights the potential of emerging thrombolytic therapies such as antagonists of fibrinolysis inhibitors to improve safety and efficacy of the treatment and prevention of acute thrombosis in patients with venous thromboembolism (VTE). A State-of-the-Art Review published on Feb.

Thrombosis 65

Thrombosis Article 65

Journal of Cardiovascular Pharmacology

FEBRUARY 28, 2024

However, despite a heterogenous substrate underlying coronary thrombosis, treatment remains identical. This article provides an overview of atherosclerotic plaque erosion characteristics and its underlying mechanisms, highlights its clinical implications, and discusses potential therapeutic strategies.

Plaque 40

Plaque Thrombosis Atherosclerosis Article 40

American College of Cardiology

FEBRUARY 1, 2025

7 The use of antiplatelet agents to prevent stent thrombosis, moderate- to high-dose statin therapy after acute coronary syndromes, or antihypertensive agents in asymptomatic patients may all be perceived by patients as not providing benefit because they may not feel the effects.8

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease CMS Hospital 40

Dr. Smith's ECG Blog

NOVEMBER 15, 2013

Here is the classic article on continuous 12-lead monitoring (in full text) showing that the ECG is a much more reliable indicator of re-occlusion than are symptoms. Here is another classic article. It is well documented with continuous 12-lead monitoring that acute re-occlusion is frequently asymptomatic.

Chest Pain 52

Chest Pain Thrombosis Myocardial Infarction STEMI 52

Cardiometabolic Health Congress

AUGUST 23, 2024

Explore the CMHC Lipid Management Hub Visit the CMHC Lipid Management Hub , where you’ll find a wealth of resources, including webinars, CME activities, expert interviews, on-demand event recordings, news articles, drug pipelines, and more, all organized by specialty focus and format.

Dementia 52

Dementia Cholesterol Risk Factors CME 52

Stroke Journal

MARCH 11, 2024

Historically, the research literature overwhelmingly emphasized the future hemorrhagic risk associated with CMBs, potentially leading to unnecessary withholding of treatments proven effective at preventing thrombosis, such as anticoagulants in patients with atrial fibrillation who happened to have some microbleeds.

Hemorrhage 40

Hemorrhage Atrial Fibrillation Thrombosis Article 40

Journal of Cardiovascular Pharmacology

APRIL 9, 2024

Clinical practice shows that a critical unmet need in the field of thrombosis prevention is the availability of anticoagulant therapy without bleeding risk. Clinical practice shows that a critical unmet need in the field of thrombosis prevention is the availability of anticoagulant therapy without bleeding risk.

Thrombosis 40

Thrombosis Article 40

Dr. Smith's ECG Blog

NOVEMBER 30, 2022

In a recent article (J Electrocardiol this year, see reference below), peak trop onin I levels in takotsubo presenting with ST Elevation were median 1.02 Note 2: This article fails to specify whether it was troponin I or T, but I contacted the institution and they used exclusively troponin I during that time period.

Plaque 52

Plaque Chest Pain Thrombosis Stenosis 52

Dr. Smith's ECG Blog

SEPTEMBER 5, 2023

The angiogram showed an open artery with 95% stenosis and thrombosis and it was stented. I would expect TIMI-3 flow (normal flow, no persistent ischemia) with a culprit in the RCA (or possibly Circumflex). I would expect that a stent would be placed. Quiz : What percent of full blown STEMI have an open artery with normal flow at angiogram?

Chest Pain 98

Chest Pain STEMI Stents Stent 98

The British Journal of Cardiology

MAY 14, 2024

The prospect of uncoupling the management of thrombosis from the bleeding risk inadvertently associated with current therapy inspired the development of agents directed towards this step in the coagulation process.

Thrombosis 40

Thrombosis Pharmacology Physiology Atrial Fibrillation 40

Dr. Smith's ECG Blog

JANUARY 27, 2024

Old ‘NSTEMI’ A history of coronary artery disease and a stent to the same territory further increases pre-test likelihood of acute coronary occlusion, including in-stent thrombosis. This is diagnostic is inferior OMI , accompanied by inferior Q waves, and with a flat ST segment in V2 that could indicate posterior extension.

Chest Pain 117

Chest Pain STEMI Aneurysm Stents 117

Journal of Cardiovascular Pharmacology

SEPTEMBER 5, 2024

This review of the evidence for bivalirudin utilization in ECMO suggests favorable outcomes in circuit-related thrombosis, bleeding, and dosing reliability. This review of the evidence for bivalirudin utilization in ECMO suggests favorable outcomes in circuit-related thrombosis, bleeding, and dosing reliability.

Laboratory 40

Laboratory Thrombosis Pharmacology Pulmonary 40

Dr. S. Venkatesan MD

APRIL 10, 2024

It is to be noted if the obstruction is due to pannus , risk of thrombosis is almost nil and safety of prosthetic balloon valvuloplasty is almost ensured.(Of Generally, overestimation risk of bleeding viz a viz with life threatening thrombosis is quiet common especially in patients with prosthetic valve. I believe, in the above case.

Aortic valve 52

Aortic valve Aortic Thrombosis Bicuspid/Mitral 52

Journal of Cardiovascular Pharmacology

NOVEMBER 11, 2024

The clinical effect of drug-drug interactions (DDIs) between antiplatelets and antiretrovirals (ART) on bleeding, thrombosis, and other major adverse cardiovascular events (MACE) is unknown.

Thrombosis 40

Thrombosis Outcomes Article 40

Journal of Cardiovascular Pharmacology

APRIL 21, 2024

Current guidelines recommend that direct anticoagulants should not be used in prevention of recurrent thrombosis in patients with antiphospholipid syndrome (APS). Current guidelines recommend that direct anticoagulants should not be used in prevention of recurrent thrombosis in patients with antiphospholipid syndrome (APS).

Myocardial Infarction 40

Myocardial Infarction Thrombosis Stroke Strokes 40

Journal of Cardiovascular Pharmacology

MARCH 24, 2024

The efficacy of Rivaroxaban in treatment of left atrial auricular thrombosis in patients with persistent AF was correlated with LAD, LAEF, LVEF, LAA-A and LAA-v. The efficacy of Rivaroxaban in treatment of left atrial auricular thrombosis in patients with persistent AF was correlated with LAD, LAEF, LVEF, LAA-A and LAA-v.

Atrial Fibrillation 40

Atrial Fibrillation Thrombosis Article 40

Journal of Cardiovascular Electrophysiology

DECEMBER 17, 2024

vs. 30.4%, p =0.07) and device related thrombosis (4.5% Both major (1.4% vs. 2.1%, p =0.72) and minor (27.8% vs. 19.4%, p =0.17) in-hospital complications were similar between the combined and control group, respectively. At 45 days, presence of peri-device leak (18.3% vs. 4.5%, p =0.96) on transesophageal echocardiogram did not differ.

Ablation 40

Ablation Arrhythmia Thrombosis Echocardiogram 40

Journal of Cardiovascular Pharmacology

NOVEMBER 22, 2023

Abstract: As the pathogenesis of arterial thrombosis often includes platelet adhesion and aggregation, antiplatelet agents are commonly used to prevent thromboembolic events. As the pathogenesis of arterial thrombosis often includes platelet adhesion and aggregation, antiplatelet agents are commonly used to prevent thromboembolic events.

Physiology 40

Physiology Thrombosis Pharmacology Technology 40

Journal of Cardiovascular Pharmacology

NOVEMBER 6, 2023

Primary endpoint of systematic review and meta-analysis is the NACE (Net Adverse Cardiac Events) and secondary are MACE (Major Adverse Cardiac Events), mortality, bleedings, myocardial infarction and stent thrombosis. Subgroup analyses included studies using only ticagrelor-based regimens and three-months duration of DAPT.

Diabetes 40

Diabetes Myocardial Infarction Thrombosis Stents 40

Dr. Smith's ECG Blog

MAY 19, 2020

Coronary thrombosis or embolism can result in MINOCA, either with or without a hypercoagulable state. The ways to tell for certain include intravascular ultrasound (to look for extra-luminal plaque with rupture) or "optical coherence tomography," something I am entirely unfamiliar with. A list of conditions that can cause this is below.

Defibrillator 52

Defibrillator Circulation Plaque Cardiac Arrest 52

The British Journal of Cardiology

OCTOBER 8, 2024

A quiet revolution without fanfare took place at a meeting, witnessed by over 1,000 people both in London and live streamed across the globe on 31 January 2024. It was unprecedented, going against received wisdom.

Coronary Artery Disease 40

Coronary Artery Disease Stents Stent Hospital 40

The British Journal of Cardiology

NOVEMBER 10, 2023

Andreas Grüntzig, an ardent angiologist crafted an indeflatable sausage-shaped dual-lumen balloon-catheter, designed its delivery to the heart, launched minimally invasive coronary intervention and taught by beaming live demonstration. Subsequent advances are just incremental tweaks and tinkers around this fully formed framework from 1978.

Stents 40

Stents Stent Coronary Artery Disease Myocardial Infarction 40

Cardiology Update

FEBRUARY 11, 2024

Bioprosthetic valve dysfunction (BVD) was categorized into structural valve deterioration (SVD), non-structural valve dysfunction (NSVD), clinical valve thrombosis, or endocarditis. No cases of clinical valve thrombosis were reported. Original article: Thyregod HGH et al. Severe SVD was defined by specific criteria.

Aortic valve 124

Aortic valve Aortic Outcomes Thrombosis 124

Cardiology Update

FEBRUARY 6, 2024

In a recent article published in JACC: Cardiovascular Interventions, investigators presented comprehensive examination of both short- and long-term stroke risks post-TAVR, offering insights into evolving trends and predictors. Original article: Okuno et al. J Am Coll Cardiol Intv 2023;16:2986–2996.

TAVR 111

TAVR Stroke Strokes Aortic valve 111

Coronary Artery Disease Journal

MARCH 7, 2024

Databases were searched for relevant articles published before 10 November 2023. Similarly, all-cause mortality, cardiovascular mortality, stent thrombosis, and acute renal insufficiency did not show significant differences between two groups. However, deciding the timing of revascularization for non-IRA in cases of MVD is uncertain.

Myocardial Infarction 40

Myocardial Infarction Ischemia Thrombosis Article 40

Journal of Cardiovascular Electrophysiology

DECEMBER 4, 2024

However, the presence of residual trabeculation did not contribute to PDL or device-related thrombosis at follow-up or affect the clinical outcomes. However, the PDL and device-related thrombosis at 45 days and 1 year were comparable between the two groups (37% vs. 23%, p =0.24; 28% vs. 31%, p =0.84; 2.1% vs. 1.4%, p =0.50; 6.9%

Thrombosis 40

Thrombosis Atrial Fibrillation Outcomes Research 40

Cardiology Update

FEBRUARY 14, 2024

In the early years of percutaneous coronary intervention (PCI), studies indicated a heightened risk of major adverse cardiac events (MACE) in patients with reduced left ventricular ejection fraction (LVEF), involving outcomes such as death, Q-wave myocardial infarction (MI), stent thrombosis, and repeat revascularization. Am Heart J.

Myocardial Infarction 52

Myocardial Infarction Coronary Artery Disease Thrombosis Research 52

Journal of Cardiovascular Pharmacology

MAY 2, 2024

The primary outcome was major adverse cardiac and cerebrovascular event (MACCE), namely a composite of death from cardiovascular causes, myocardial infarction (MI), stroke, stent thrombosis within 12 month. The secondary outcome was Bleeding Academic Research Consortium (BARC) scale bleeding events within 12 months.

Outcomes 40

Outcomes Myocardial Infarction Thrombosis Academic 40

Frontiers in Cardiovascular Medicine

NOVEMBER 28, 2024

0.85, P = 0.004), target vessel revascularization (TVR) (P = 0.01), target lesion revascularization (TLR) (P = 0.03) and stent thrombosis (ST) (P = 0.002) in the experimental group (IVUS-guidance) was lower than that in the control group (non-IVUS-guidance). The results showed that the incidence of MACE (RR: 0.63, 95% CI: 0.49–0.82,

Stents 59

Stents Stent Coronary Artery Disease Myocardial Infarction 59

Dr. Smith's ECG Blog

MARCH 8, 2025

Angiography was technically challenging as the patient was receiving CPR, but the cardiologist suspected acute stent thrombosis and initiated cangrelor, although no repeat angiography was able to be obtained. During the resuscitation, she received amiodarone 450 mg IV, lidocaine 100 mg IV, and magnesium 6 g IV.

Cardiomyopathy 75

Cardiomyopathy Myocardial Infarction Defibrillator Bradycardia 75